{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T18:30:17Z","timestamp":1789065017617,"version":"build-2803163510"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T00:00:00Z","timestamp":1700524800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.msard.2023.105147","type":"journal-article","created":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T05:52:34Z","timestamp":1700545954000},"page":"105147","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Neutropaenia complications from Ocrelizumab and Rituximab treatment"],"prefix":"10.1016","volume":"81","author":[{"given":"Venus","family":"Pang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabil","family":"Seery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robb","family":"Wesselingh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracie","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Dwyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassie","family":"Nesbitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Rath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Perera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Bridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Skibina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian J.","family":"Bosco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vilija","family":"Jokubaitis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Marriott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut","family":"Butzkueven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anneke","family":"Van Der Walt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Massey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Sutton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6404-9768","authenticated-orcid":false,"given":"Mastura","family":"Monif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2023.105147_bib0020","first-page":"68","article-title":"Neutropenia complicating anti-CD20 treatment in patients with multiple sclerosis: a retrospective case series and a systematic review of reported cases","author":"AD","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.105147_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102155","article-title":"Late-onset neutropenia in a multiple sclerosis patient after first dose ocrelizumab switched from rituximab","volume":"43","author":"Auer","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.105147_bib0017","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1177\/1941874420936438","article-title":"Severe delayed-onset neutropenia induced by Ocrelizumab","volume":"11","author":"Baird-Gunning","year":"2020","journal-title":"Neurohospitalist"},{"key":"10.1016\/j.msard.2023.105147_bib0013","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1177\/1352458506070775","article-title":"MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis","volume":"12","author":"Butzkueven","year":"2006","journal-title":"Multiple Sclerosis J."},{"key":"10.1016\/j.msard.2023.105147_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102802","article-title":"Ocrelizumab depletes T-lymphocytes more than rituximab in multiple sclerosis","volume":"49","author":"Capasso","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.105147_bib0012","series-title":"Proceedings of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)","first-page":"11","article-title":"Cases reported as progressive multifocal leukoencephalopathy in ocrelizumab-treated patients with multiple sclerosis","author":"Clifford","year":"2019"},{"key":"10.1016\/j.msard.2023.105147_bib0015","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1212\/WNL.0000000000006924","article-title":"Late-onset neutropenia following ocrelizumab therapy for multiple sclerosis","volume":"92","author":"Cohen","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2023.105147_bib0008","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s40263-018-0488-6","article-title":"Efficacy and safety of the newer multiple sclerosis drugs approved since 2010","volume":"32","author":"Faissner","year":"2018","journal-title":"CNS Drugs"},{"key":"10.1016\/j.msard.2023.105147_bib0007","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/ana.25119","article-title":"B-cell therapy for multiple sclerosis: entering an era","volume":"83","author":"Greenfield","year":"2018","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2023.105147_bib0014","doi-asserted-by":"crossref","first-page":"e1546","DOI":"10.1212\/WNL.0000000000012700","article-title":"Safety of Ocrelizumab in patients with relapsing and primary progressive multiple sclerosis","volume":"97","author":"Hauser","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2023.105147_bib0004","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1080\/14712598.2017.1347632","article-title":"Ocrelizumab: a B-cell depleting therapy for multiple sclerosis","volume":"17","author":"Jakimovski","year":"2017","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.msard.2023.105147_bib0026","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.ejim.2006.05.002","article-title":"Parvovirus B19 reactivation presenting as neutropenia after rituximab treatment","volume":"17","author":"Klepfish","year":"2006","journal-title":"Eur. J. Intern. Med."},{"key":"10.1016\/j.msard.2023.105147_bib0024","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1182\/blood.V95.10.3219","article-title":"Chronic neutropenia mediated by Fas ligand","volume":"95","author":"Liu","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.msard.2023.105147_bib0009","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.msard.2019.01.044","article-title":"Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies","volume":"30","author":"Mayer","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.105147_bib0025","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1080\/10428190600649349","article-title":"Late-onset neutropenia following rituximab","volume":"47","author":"McLaughlin","year":"2006","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.msard.2023.105147_bib0003","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1080\/25785826.2021.1952543","article-title":"B-cell depletion therapy for multiple sclerosis","volume":"45","author":"Miyazaki","year":"2022","journal-title":"Immunol. Med."},{"key":"10.1016\/j.msard.2023.105147_bib0011","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1007\/s10067-016-3313-y","article-title":"Rituximab associated late-onset neutropenia\u2014a rheumatology case series and review of the literature","volume":"35","author":"Monaco","year":"2016","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.msard.2023.105147_bib0027","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1212\/WNL.54.11.2147","article-title":"Multiple sclerosis flares associated with recombinant granulocyte colony-stimulating factor","volume":"54","author":"Openshaw","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2023.105147_bib0023","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0145-2126(01)00183-7","article-title":"Evidence for T-large granular lymphocyte-mediated neutropenia in Rituximab-treated lymphoma patients: report of two cases","volume":"26","author":"Papadaki","year":"2002","journal-title":"Leuk. Res."},{"key":"10.1016\/j.msard.2023.105147_bib0002","doi-asserted-by":"crossref","first-page":"eaav7188","DOI":"10.1126\/science.aav7188","article-title":"Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility","volume":"365","author":"Patsopoulos","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.msard.2023.105147_bib0019","doi-asserted-by":"crossref","first-page":"e05299","DOI":"10.1002\/ccr3.5299","article-title":"Severe late-onset neutropenia induced by ocrelizumab in a multiple sclerosis patient: a case report","volume":"10","author":"Rauniyar","year":"2022","journal-title":"Clin. Case Rep."},{"key":"10.1016\/j.msard.2023.105147_bib0010","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s40263-021-00810-3","article-title":"Predicting infection risk in multiple sclerosis patients treated with Ocrelizumab: a retrospective cohort study","volume":"35","author":"Seery","year":"2021","journal-title":"CNS Drugs"},{"key":"10.1016\/j.msard.2023.105147_bib0005","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1177\/1756285615601933","article-title":"The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects","volume":"9","author":"Sorensen","year":"2015","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2023.105147_bib0021","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1038\/sj.leu.2405077","article-title":"Lymphocyte subpopulation imbalances, bone marrow hematopoiesis and histopathology in rituximab-treated lymphoma patients with late-onset neutropenia","volume":"22","author":"Stamatopoulos","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.msard.2023.105147_bib0001","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/S0140-6736(18)30481-1","article-title":"Multiple sclerosis","volume":"391","author":"Thompson","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2023.105147_bib0022","first-page":"89","article-title":"Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature","author":"Wolach","year":"2010","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.msard.2023.105147_bib0016","unstructured":"Zanettaa C., Robottia M., Nozzolilloa A., et al. Late onset absolute neutropenia associated with ocrelizumab treatment in multiple sclerosis: a case report and review of the literature."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482300648X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482300648X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T01:02:49Z","timestamp":1719968569000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221103482300648X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":27,"alternative-id":["S221103482300648X"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2023.105147","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neutropaenia complications from Ocrelizumab and Rituximab treatment","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2023.105147","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105147"}}